Distinguishing Impetigo from HSV-1 and Treatment Approach
Impetigo and HSV-1 can be reliably distinguished by their characteristic clinical presentations: impetigo presents with honey-colored crusts on an erythematous base, while HSV-1 shows grouped vesicles that progress to ulcers with a clear prodrome of pain or tingling.
Clinical Differentiation
Impetigo Features 1, 2, 3
- Honey-colored crusts are pathognomonic for nonbullous impetigo (70% of cases) 2
- Lesions commonly affect the face and extremities 1, 2
- Often secondary infection of insect bites, eczema, or other skin breaks 2
- No prodrome or sensory symptoms before lesion appearance 2
- Bullous impetigo (30% of cases) presents with large, flaccid bullae, typically in intertriginous areas 2
- Most common in children 2-5 years old 2, 3
HSV-1 Features 4, 5, 6
- Grouped vesicles on an erythematous base that evolve to ulcers and crusts 6
- Clear sensory prodrome (tingling, pain, burning) precedes lesion appearance by hours 4, 5
- Lesions progress through distinct stages: papule → vesicle → ulcer → crust over 7-10 days 4
- Recurrent episodes at the same anatomic site are characteristic 4, 6
- Primary HSV gingivostomatitis presents with fever, tender lymphadenopathy, and painful oral ulcers 5, 6
- Lesions typically on lips and perioral area for herpes labialis 4, 6
Diagnostic Confirmation
When Laboratory Testing is Needed 1, 4, 7
- Impetigo: Gram stain and culture are recommended but treatment without testing is reasonable in typical cases 7
- HSV-1: Laboratory confirmation should be pursued when diagnosis is uncertain, as clinical diagnosis has poor sensitivity and specificity 4
- HSV testing options (in order of preference): PCR (most sensitive), viral culture, direct fluorescent antibody, or Tzanck test 4, 6
Treatment Algorithms
Impetigo Treatment 1, 7, 2
For limited lesions:
- Topical mupirocin is the best topical agent (A-I recommendation) 1
- Apply three times daily for 7 days 2
- Alternative topical agents: retapamulin or fusidic acid 2
For numerous lesions or topical treatment failure:
- Oral antibiotics for 7 days active against both S. aureus and S. pyogenes 1, 7
- First-line options: Dicloxacillin or cephalexin (for methicillin-susceptible S. aureus) 7
- If MRSA suspected: Doxycycline, clindamycin, or trimethoprim-sulfamethoxazole 1, 7
- Avoid penicillin alone as it is inadequate for S. aureus 3
HSV-1 Treatment 8, 6
First clinical episode (primary infection):
- Acyclovir 400 mg orally three times daily for 7-10 days, OR 8
- Valacyclovir 1 g orally twice daily for 7-10 days, OR 8
- Famciclovir 250 mg orally three times daily for 7-10 days 8
- Treatment may be extended if healing incomplete after 10 days 8
Recurrent episodes (herpes labialis):
- Episodic therapy: Start at first sign of prodrome 8, 6
- Suppressive therapy (for ≥6 recurrences/year): 8
Topical antivirals (acyclovir, penciclovir, docosanol) are substantially less effective than oral therapy and their use is discouraged 8, 6
Critical Pitfalls to Avoid
Impetigo Management 1, 7, 2
- Do not use topical disinfectants - they are inferior to antibiotics 3
- Consider MRSA prevalence in your area when selecting empiric therapy 1, 7
- Re-evaluate in 24-48 hours if no clinical response to ensure correct diagnosis and treatment 1
- Macrolide resistance in S. pyogenes is increasing (8-9%), though clindamycin resistance remains low 1
HSV-1 Management 4, 8, 6
- Topical acyclovir is inadequate - always use systemic therapy for meaningful clinical benefit 8
- Early treatment is essential - efficacy decreases significantly if started >48 hours after lesion onset 6
- Type-specific testing has prognostic importance: HSV-1 genital infections recur much less frequently than HSV-2 8
- In immunocompromised patients, expect more severe, prolonged disease and potential acyclovir resistance 4